Blinded Contractility Analysis in hiPSC-Cardiomyocytes in Engineered Heart Tissue Format: Comparison With Human Atrial Trabeculae
Open accessThe DOI matches its Crossref record; 56 of the 59 references it cites were found in a registry or an index.
Abstract
Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) may serve as a new assay for drug testing in a human context, but their validity particularly for the evaluation of inotropic drug effects remains unclear. In this blinded analysis, we compared the effects of 10 indicator compounds with known inotropic effects in electrically stimulated (1.5 Hz) hiPSC-CM-derived 3-dimensional engineered heart tissue (EHT) and human atrial trabeculae (hAT). Human EHTs were prepared from iCell hiPSC-CM, hAT obtained at routine heart surgery. Mean intra-batch variation coefficient in baseline force measurement was 17% for EHT and 49% for hAT. The PDE-inhibitor milrinone did not affect EHT contraction force, but increased force in hAT. Citalopram (selective serotonin reuptake inhibitor), nifedipine (LTCC-blocker) and lidocaine (Na+ channel-blocker) had negative inotropic effects on EHT and hAT. Formoterol (beta-2 agonist) had positive lusitropic but no inotropic effect in EHT, and positive clinotropic, lusitropic, and inotropic effects in hAT. Tacrolimus (calcineurin-inhibitor) had a negative inotropic effect in EHTs, but no effect in hAT. Digoxin (Na+-K+-ATPase-inhibitor) showed a positive inotropic effect only in EHTs, but no effect in hAT probably due to short incubation time. Ryanodine (ryanodine receptor-inhibitor) reduced contraction force in both models. Rolipram and acetylsalicylic acid showed noninterpretable results in hAT. Contraction amplitude and kinetics were more stable over time and less variable in hiPSC-EHTs than hAT. HiPSC-EHT faithfully detected cAMP-dependent and -independent positive and negative inotropic effects, but limited beta-2 adrenergic or PDE3 effects, compatible with an immature CM phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Blinded drug screening of 10 compounds. Average contraction peaks. A, Average contraction peaks of electrically stimulated hiPSC-EHTs in modified Tyrode‘s solution (1.0 mM Ca2+) indicating relative force normalized to baseline over time. Four to eight EHTs per average peak. Black: baseline. Red: compound at indicated concentration (30 µM milrinone, 30 µM rolipram, 10 µM citalopram, 0.1 µM nifedipine, 30 µM lidocaine, 0.3 µM formoterol, 30 µM tacrolimus, 0.3 µM digoxin, 30 µM acetylsalicylic acid, 30 µM, and 0.3 µM [blue] ryanodine). B, Average contraction peaks of electrically stimulated hAT in modified Tyrode‘s solution (1.8 mM Ca2+). Four to six hAT per average peak. Black: baseline. Green: compound at indicated concentration (30 µM milrinone, 30 µM rolipram, 10 µM citalopram, 3 µM nifedipine, 30 µM lidocaine, 3 µM formoterol, 30 µM tacrolimus, 3 µM digoxin, 30 µM acetylsalicylic acid, 30 µM, and 3 µM [blue] ryanodine). Please note the different ordinate scale in the milrinone graph of the hAT measurement and the different concentrations of nifedipine, formoterol and digoxin in hiPSC-EHT versus hAT.](https://figures.cochat.ai/paper-figures/7181a45016ca45adb931ab13af475cdb/blinded-contractility-analysis-in-hipsc-cardiomyocytes-in-engineered-heart-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Prior cardiac tissue engineering studies have shown this in the context of arrhythmogenicity [33], contractility [14,34] and recapitulation of disease phenotypes [12,48].”
From Bioengineering an electro-mechanically functional miniature ventricular heart chamber from human pluripotent stem cells (2018) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcium Sparks: Elementary Events Underlying Excitation-Contraction Coupling in Heart Muscle
Cheng, H., Lederer, W. J., & Cannell, M. B. (1993) · Science · doi:10.1126/science.8235594 · Cited by 1,935 · cited 2×
“At low (nanomolar) concentrations, it sensitizes the channel to Ca2þ and promotes RyR2 opening, in higher concentration it inhibits its open probability (Cheng et al., 1993).”
BackgroundDevelopment of a drug screening platform based on engineered heart tissue
Hansen, A., Eder, A., Bönstrup, M., Flato, M., Mewe, M., Schaaf, S., Aksehirlioglu, B., Schwörer, A., Uebeler, J., & Eschenhagen, T. (2010) · Circulation Research · doi:10.1161/circresaha.109.211458 · Cited by 510 · cited 2×
“EHTs were generated in agarose casting molds with solid silicone racks as previously described (Schaaf et al., 2014; Hansen et al., 2010).”
MethodSelf-citationHuman Engineered Heart Tissue: Analysis of Contractile Force
Mannhardt, I., Breckwoldt, K., Letuffe-Brenière, D., Schaaf, S., Schulz, H., Neuber, C., Benzin, A., Werner, T., Eder, A., Schulze, T., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.04.011 · Cited by 398 · cited 11×
“seem to mature in the EHT format in some structural and functional parameters (Mannhardt et al., 2016; Uzun et al., 2016), further means to improve maturation are imperative to boost the predictive value of hiPSC-CM in drug testing.”
BackgroundMethodResultSelf-citationPrediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes
Braam, S. R., Tertoolen, L., van de Stolpe, A., Meyer, T., Passier, R., & Mummery, C. L. (2010) · Stem Cell Research · doi:10.1016/j.scr.2009.11.004 · Cited by 368 · cited 1×
“Different test systems have been published for hiPSC-CM including measurement of impedance (Guo et al., 2011; Scott et al., 2014), field potentials (FP) (Braam et al., 2010; Caspi et al., 2009; Harris et al., 2013; VC The Author 2017.”
MethodHirt, M. N., Boeddinghaus, J., Mitchell, A., Schaaf, S., Börnchen, C., Müller, C., Schulz, H., Hubner, N., Stenzig, J., Stoehr, A., et al. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.05.009 · Cited by 352 · cited 1×
“Electrical pacing was performed with carbon pacing electrodes as recently described (Hirt et al., 2014; 1–2 Hz).”
MethodSelf-citationNavarrete, E. G., Liang, P., Lan, F., Sanchez-Freire, V., Simmons, C., Gong, T., Sharma, A., Burridge, P. W., Patlolla, B., Lee, A. S., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000570 · Cited by 302 · cited 1×
“For commercial re-use, please contact journals.permissions@oup.com 164 Navarrete et al., 2013), calcium and voltage measurements (Hwang et al., 2015; Lee et al., 2012; Lopez-Izquierdo et al., 2014), single cell shortening (Pointon et al., 2015) and electrophysiology (Hoekstra et al., 2012).”
Denning, C., Borgdorff, V., Crutchley, J., Firth, K. S. A., George, V., Kalra, S., Kondrashov, A., Hoang, M. D., Mosqueira, D., Patel, A., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.10.014 · Cited by 293 · cited 2×
“In hiPSC-CM models isoprenaline was frequently used and was reported to lead to small effects across different models (effect size: <þ100%; Denning et al., 2016) compared to human nonfailing heart tissue (effect sizes more than 200%; Bohm et al., 1991; Mügge et al., 1985; Schotten et al., 2001),…”
MethodCrumb, W. J., Vicente, J., Johannesen, L., & Strauss, D. G. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.03.009 · Cited by 288 · cited 2×
“, 2014) and others (Crumb et al., 2016) have therefore implemented a “relevance threshold”.”
BackgroundGuo, L., Abrams, R. M. C., Babiarz, J. E., Cohen, J. D., Kameoka, S., Sanders, M. J., Chiao, E., & Kolaja, K. L. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr158 · Cited by 272 · cited 2×
“Different test systems have been published for hiPSC-CM including measurement of impedance (Guo et al., 2011; Scott et al., 2014), field potentials (FP) (Braam et al., 2010; Caspi et al., 2009; Harris et al., 2013; VC The Author 2017.”
MethodBlinova, K., Stohlman, J., Vicente, J., Chan, D., Johannesen, L., Hortigon-Vinagre, M. P., Zamora, V., Smith, G., Crumb, W. J., Pang, L., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfw200 · Cited by 272
Cited by
Challenges and opportunities for the next generation of cardiovascular tissue engineering
Cho, S., Discher, D. E., Leong, K. W., Vunjak-Novakovic, G., & Wu, J. C. (2022) · Nature Methods · doi:10.1038/s41592-022-01591-3 · Cited by 176
Li, R. A., Keung, W., Cashman, T. J., Backeris, P. C., Johnson, B. V., Bardot, E. S., Wong, A. O. T., Chan, P. K. W., Chan, C. W. Y., & Costa, K. D. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.024 · Cited by 175
In vitro generation of functional murine heart organoids via FGF4 and extracellular matrix
Lee, J., Sutani, A., Kaneko, R., Takeuchi, J., Sasano, T., Kohda, T., Ihara, K., Takahashi, K., Yamazoe, M., Morio, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18031-5 · Cited by 154
Natural Biomaterials for Cardiac Tissue Engineering: A Highly Biocompatible Solution
Majid, Q. A., Fricker, A. T. R., Gregory, D. A., Davidenko, N., Hernandez Cruz, O., Jabbour, R. J., Owen, T. J., Basnett, P., Lukasiewicz, B., Stevens, M., et al. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.554597 · Cited by 131
Engineered Cardiac Tissues Generated in the Biowire II: A Platform for Human-Based Drug Discovery
Feric, N. T., Pallotta, I., Singh, R., Bogdanowicz, D. R., Gustilo, M. M., Chaudhary, K. W., Willette, R. N., Chendrimada, T. P., Xu, X., Graziano, M. P., et al. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz168 · Cited by 96
“none as compared to human heart tissue (Mannhardt et al., 2017); suggesting maturity in the adrenergic pathway and/or enhanced PDE3A expression in fibroblast containing ECTs.”
BackgroundTowards chamber specific heart-on-a-chip for drug testing applications
Zhao, Y., Rafatian, N., Wang, E. Y., Wu, Q., Lai, B. F. L., Lu, R. X., Savoji, H., & Radisic, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.12.002 · Cited by 97
“9μM for Ca2+ transients[28] Ca2+ EC50=16nM [148] EC50 = 50–200nM (inotropic; ventricular muscle)[139, 153] Ca2+ EC50=39 nM [146] EC50 <100nM (inotropic)[151]”
Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format
Mannhardt, I., Saleem, U., Mosqueira, D., Loos, M. F., Ulmer, B. M., Lemoine, M. D., Larsson, C., Améen, C., de Korte, T., Vlaming, M. L. H., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.09.002 · Cited by 73
Self-citationvan Meer, B. J., Krotenberg, A., Sala, L., Davis, R. P., Eschenhagen, T., Denning, C., Tertoolen, L. G. J., & Mummery, C. L. (2019) · Nature Communications · doi:10.1038/s41467-019-12354-8 · Cited by 73
Self-citationPitoulis, F. G., Watson, S. A., Perbellini, F., & Terracciano, C. M. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz341 · Cited by 74
Keung, W., Chan, P. K. W., Backeris, P. C., Lee, E. K., Wong, N., Wong, A. O. T., Wong, G. K. Y., Chan, C. W. Y., Fermini, B., Costa, K. D., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1385 · Cited by 54
“While a number of these engineered constructs have been tested to display responses to certain common drugs and recapitulate specific phenotypes as disease models, limited systematic studies have been performed to comprehensively and objectively evaluate their predictability as preclinical drug screening platforms by…”
BackgroundResultRibeiro, A. J. S., Guth, B. D., Engwall, M. J., Eldridge, S. R., Foley, C. M., Guo, L., Gintant, G. A., Koerner, J. E., Parish, S. T., Pierson, J. B., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00934 · Cited by 58
Myocardial Contractility: Historical and Contemporary Considerations
Muir, W. W., & Hamlin, R. L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00222 · Cited by 47
Heart-derived collagen promotes maturation of engineered heart tissue
Tani, H., Kobayashi, E., Yagi, S., Tanaka, K., Haga, K., Shibata, S., Moritoki, N., Takatsuna, K., Moriwaki, T., Sekine, O., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122174 · Cited by 48
Heart-on-a-chip systems: disease modeling and drug screening applications
Butler, D., & Reyes, D. R. (2024) · Lab on a Chip · doi:10.1039/d3lc00829k · Cited by 47
de Korte, T., Katili, P. A., Yusof, N. A. N. M., van Meer, B. J., Saleem, U., Burton, F. L., Smith, G. L., Clements, P., Mummery, C. L., Eschenhagen, T., et al. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023309 · Cited by 45
Self-citationThomas, D., Shenoy, S., & Sayed, N. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.607364 · Cited by 39
“In two recent studies, EHTs derived from iPSC-CMs demonstrated a high force-frequency relationship and physiological response to ionotropic and chronotropic drugs (Mannhardt et al., 2017; RonaldsonBouchard et al., 2018).”
BackgroundMechanobiology Assays with Applications in Cardiomyocyte Biology and Cardiotoxicity
Blair, C. A., & Pruitt, B. L. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901656 · Cited by 37
Translational investigation of electrophysiology in hypertrophic cardiomyopathy
Flenner, F., Jungen, C., Küpker, N., Ibel, A., Kruse, M., Koivumäki, J. T., Rinas, A., Zech, A. T. L., Rhoden, A., Wijnker, P. J. M., et al. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.04.009 · Cited by 35
Self-citationA Change of Heart: Human Cardiac Tissue Engineering as a Platform for Drug Development
Bremner, S. B., Gaffney, K. S., Sniadecki, N. J., & Mack, D. L. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01668-7 · Cited by 35
Highly specific and non-invasive imaging of Piezo1-dependent activity across scales using GenEPi
Yaganoglu, S., Kalyviotis, K., Vagena-Pantoula, C., Jülich, D., Gaub, B. M., Welling, M., Lopes, T., Lachowski, D., Tang, S. S., Hernández, A. E. D. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40134-y · Cited by 30
Piezo-bending actuators for isometric or auxotonic contraction analysis of engineered heart tissue
Mannhardt, I., Warncke, C., Trieu, H. K., Müller, J. W., & Eschenhagen, T. (2018) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.2755 · Cited by 31
“Human EHT replicated responses to physiological or pharmacological stimuli similar to the human heart (Huebsch et al., 2016; Mannhardt et al., 2016; Mannhardt et al., 2017) and could be a new platform for preclinical cardiac drug safety screening.”
BackgroundSelf-citationGuth, B. D., Engwall, M. J., Eldridge, S. R., Foley, C. M., Guo, L., Gintant, G. A., Koerner, J. E., Parish, S. T., Pierson, J. B., Ribeiro, A. J. S., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00884 · Cited by 36
Feaster, T. K., Casciola, M., Narkar, A., & Blinova, K. (2021) · Physiological Reports · doi:10.14814/phy2.15085 · Cited by 29
Cardiac macrotissues-on-a-plate models for phenotypic drug screens
Meyer, T., Tiburcy, M., & Zimmermann, W. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.03.002 · Cited by 32
Multiparametric Mechanistic Profiling of Inotropic Drugs in Adult Human Primary Cardiomyocytes
Abi‐Gerges, N., Indersmitten, T., Truong, K., Nguyen, W., Ratchada, P., Nguyen, N., Page, G., Miller, P. E., & Ghetti, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-64657-2 · Cited by 30
Wheelwright, M., Mikkila, J. L., Bedada, F. B., Mandegar, M. A., Thompson, B. R., & Metzger, J. M. (2020) · Stem Cells · doi:10.1002/stem.3235 · Cited by 28
“groups working with hiPSC-CMs have noted altered responsiveness to adrenergic agonists.(44) Thus, increased β-adrenergic responsivity by cTnI induction represents a physiologically relevant advance in hiPSC-CMs.”
BackgroundCharwat, V., Charrez, B., Siemons, B. A., Finsberg, H. N. T., Jæger, K. H., Edwards, A. G., Huebsch, N., Wall, S., Miller, E. W., Tveito, A., et al. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00088 · Cited by 24
Liu, S., Fang, C., Zhong, C., Li, J., & Xiao, Q. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09835-4 · Cited by 22
“(Mannhardt et al. 2017) Importantly, ECTs can also be used to evaluate the remdesivir-induced cardiotoxicity in patient with COVID-19 and test drug candidates that could prevent or limit the remdesivir-induced cardiotoxicity.”
BackgroundMurphy, J. F., Mayourian, J., Stillitano, F., Munawar, S., Broughton, K. M., Agulló-Pascual, E., Sussman, M. A., Hajjar, R. J., Costa, K. D., & Turnbull, I. C. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1486-4 · Cited by 25
iPSC-cardiomyocytes in the preclinical prediction of candidate pharmaceutical toxicity
Lee, T. Y. T., Coles, J. G., & Maynes, J. T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1308217 · Cited by 21
Cardiovascular microphysiological systems (CVMPS) for safety studies – a pharma perspective
Pointon, A., Maher, J. M., Davis, M., Baker, T. K., Cichocki, J. A., Ramsden, D., Hale, C. M., Kolaja, K. L., Lévesque, P., Sura, R., et al. (2021) · Lab on a Chip · doi:10.1039/d0lc01040e · Cited by 22
Arefin, A., Mendoza, M., Dame, K., Garcia, M. I., Strauss, D. G., & Ribeiro, A. J. S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1212092 · Cited by 20
Microengineered systems with iPSC-derived cardiac and hepatic cells to evaluate drug adverse effects
Dame, K., & Ribeiro, A. J. S. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220959598 · Cited by 24
Yadid, M., Hagel, M., Beldjilali‐Labro, M., Roi, B. L., Flaxer, C., Flaxer, E., Barnea, A. R., Tejman‐Yarden, S., Silberman, E., Li, X., et al. (2023) · Advanced Science · doi:10.1002/advs.202207498 · Cited by 19
Satsuka, A., & Kanda, Y. (2019) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201020666190628143345 · Cited by 20
Abi‐Gerges, N., Miller, P. E., & Ghetti, A. (2019) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666191210142023 · Cited by 19
Rhoden, A., Schulze, T., Pietsch, N., Christ, T., Hansen, A., & Eschenhagen, T. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00534.2021 · Cited by 21
Self-citationHan, J., Heinson, Y. W., Chua, C. J., Liu, W., & Entcheva, E. G. (2023) · Communications Biology · doi:10.1038/s42003-023-05627-y · Cited by 19
“Comprehensive studies of over 700 hiPSC lines from over 300 donors have observed variable molecular signatures — both donor-speci fi c and of unknown sources 18,19 .”
Regulation of ICa,L and force by PDEs in human‐induced pluripotent stem cell‐derived cardiomyocytes
Saleem, U., Ismaili, D., Mannhardt, I., Pinnschmidt, H. O., Schulze, T., Christ, T., Eschenhagen, T., & Hansen, A. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15032 · Cited by 18
“In the course of a blinded analysis of 10 compounds, rolipram showed a positive lusitropic and inotropic effect in contrast to milrinone, suggesting a predominance of PDE4 over PDE3 in this model (Mannhardt et al., 2017).”
ResultSelf-citationAssessment of Cardiotoxicity With Stem Cell-based Strategies
Stoter, A. M. S., Hirt, M. N., Stenzig, J., & Weinberger, F. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.08.012 · Cited by 18
Hortigon-Vinagre, M. P., Zamora, V., Burton, F. L., & Smith, G. L. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000937 · Cited by 17
Ismaili, D., Schulz, C., Horváth, A., Koivumäki, J. T., Mika, D., Hansen, A., Eschenhagen, T., & Christ, T. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1132165 · Cited by 16
“hyperpolarization-activated funny current (If) in hiPSC-CM EHT (Mannhardt et al., 2017).”
BackgroundSelf-citationHinata, Y., Kagawa, Y., Kubo, H., Kato, E., Baba, A., Sasaki, D., Matsuura, K., Sawada, K., & Shimizu, T. (2022) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2022.107228 · Cited by 14
Contractility assessment using aligned human iPSC-derived cardiomyocytes
Satsuka, A., Ribeiro, A. J. S., Kawagishi, H., Yanagida, S., Hirata, N., Yoshinaga, T., Kurokawa, J., Sugiyama, A., Strauss, D. G., & Kanda, Y. (2024) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2024.107530 · Cited by 11
Mekies, L. N., Regev, D., Eisen, B., Fernández-García, J., Baskin, P., Jehuda, R. B., Shulman, R., Reiter, I., Palty, R., Arad, M., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16341 · Cited by 11
Carvalho, A. B., Coutinho, K. C. D. S., Barbosa, R. A. Q., de Campos, D. B. P., Leitão, I. D. C., Pinto, R. S., dos Santos, D. S., Farjun, B., Araujo, D. S., Mesquita, F., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1077069 · Cited by 10
Development and application of 3D cardiac tissues derived from human pluripotent stem cells
Ohno, M., Tani, H., & Tohyama, S. (2025) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101049 · Cited by 9
de Korte, T., Johnson, B. B., Kosmidis, G., Samson-Couterie, B., Mol, M. P. H., van Helden, R. W. J., Razaghi, E., François, L., Meraviglia, V., Yiangou, L., et al. (2025) · Trends in biotechnology · doi:10.1016/j.tibtech.2025.11.016 · Cited by 10
Obal, D., & Wu, J. C. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15228 · Cited by 8
“Multiple anaesthetics (e.g., ketamine, nitrous oxide, and methadone) mediate their hypnotic effect through NMDA receptors.”
Keung, W., & Cheung, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.650039 · Cited by 7
Enhanced drug classification using machine learning with multiplexed cardiac contractility assays
Aghavali, R., Roberts, E. G., Kurokawa, Y. K., Mak, E., Chan, M. Y. C., Wong, A. O. T., Li, R. A., & Costa, K. D. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107459 · Cited by 6
Saotome, H., Yatsuka, Y., Minowa, O., Shinotsuka, K., Tsuchida, K., Hirose, H., Dai, K., Tokuno, H., Hayakawa, T., Hiranuma, H., et al. (2024) · Biomedical Materials · doi:10.1088/1748-605x/ad525d · Cited by 4
“Meanwhile, in FCMs, milrinone was not able to maintain CV and AMP [44, 45].”
BackgroundYıldırım, Y., Degener, L., Reuter, L., Petersen, J., Gabel, L., Sommer, A., Pahrmann, C., Reichenspurner, H. C., & Pecha, S. (2024) · Artificial Organs · doi:10.1111/aor.14833 · Cited by 4
Koivisto, M., Mosallaei, M., Toimela, T., Tuukkanen, S., & Heinonen, T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.871569 · Cited by 4
Hinata, Y., Sasaki, D., Matsuura, K., & Shimizu, T. (2024) · Physiological Reports · doi:10.14814/phy2.70152 · Cited by 3
“The compound test concentration was determined based on the studies by Mannhardt et al. (2016); Mannhardt et al. (2017); Mannhardt et al. (2020); Saleem et al. (2020); Arai et al. (2020).”
Neste, C. V., Wiley, K. A., Chang, S. W., Borrello, J. A., Turnbull, I. C., & Costa, K. D. (2023) · Journal of Visualized Experiments · doi:10.3791/64368 · Cited by 3
Bruyneel, A. A. N., Muser, T., Parthasarathy, V., Feyen, D. A. M., & Mercola, M. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-20047-3_2 · Cited by 3
Hinata, Y., Kagawa, Y., Seno, T., Kubo, H., Kato, E., Baba, A., Sasaki, D., Matsuura, K., Shimizu, T., & Sawada, K. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf167 · Cited by 2
Folkmanaite, M., Zhou, X., Koschinski, A., Hong, W., Casini, M., Koch, M., Ravens, U., Peyronnet, R., Zaccolo, M., & Rodríguez, B. (2026) · The Journal of Physiology · doi:10.1113/jp288623 · Cited by 1
The role of MAP4K4 in cardiac muscle cell death
Jenkins, M. (2018) · Spiral (Imperial College London) · doi:10.25560/62638
Experimental models and model organisms in cardiac electrophysiology: Opportunities and challenges
(2023) · Frontiers research topics · doi:10.3389/978-2-8325-3523-3
Functional modelling of arrhythmias with human cardiac organoids
Pocock, M. L. (2024) · Queensland University of Technology · doi:10.5204/thesis.eprints.247495
Success and Challenges with Models for Cardiac Translational Research
Kettenhofen, R. F., & Neubauer, J. C. (2024) · Springer eBooks · doi:10.1007/978-3-030-73317-9_136-1
Highly specific and non-invasive imaging of Piezo1-dependent activity across scales using GenEPi
(2024) · European Light Microscopy Initiative Meeting (ELMI) · doi:10.22443/rms.elmi2024.173
Spratt, M. (2024) · Queensland University of Technology · doi:10.5204/thesis.eprints.250821 · Cited by 1
Success and Challenges with Models for Cardiac Translational Research
Kettenhofen, R. F., & Neubauer, J. C. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_136
Positive inotropic effects of serotonin in atrial EHT: further proof for an atrial phenotype?
Sönmez, M. I., Nandudu, M., Brunnbauer, P., Schulz, C., Klampe, B., Schulze, T., Hansen, A., Eschenhagen, T., & Christ, T. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04619-5
“The contraction peaks were analyzed in terms of frequency and force and were measured at 37 °C. EHTs were incubated with 0.6 mM Ca 2+ for 30–45 min to facilitate detection of positive inotropic effects (Mannhardt et al. 2017).”
InfluentialSelf-citationBiowire II Platform: High Fidelity Heart-on-a-chip for Drug Screening and Disease Modeling
Zhao, Y. (2019) · TSpace (University of Toronto)
Eschenhagen, T. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag126
Self-citationAlmeida, N., Sum-Coffey, V., Costello, P., Madden, C., Devitt, S., Mukkunda, S. R., Keshava, B. B., Sunil, S., Riley, L. G., Deely, S., et al. (2026) · Biomedical Microdevices · doi:10.1007/s10544-026-00839-5
“Changes in beat rate can mask or distort underlying electrophysiological issues, making it difficult to determine if a drug effect is direct or merely a consequence of the altered rate (Laurila et al., 2016; Mannhardt et al., 2017).”
Influential
Metadata
- Authors
- Mannhardt, I., Eder, A., Dumotier, B., Prondzynski, M., Krämer, E., Traebert, M., Söhren, K.-D., Flenner, F., Stathopoulou, K., Lemoine, M. D., Carrier, L., Christ, T., Eschenhagen, T., & Hansen, A.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- Novartis (Switzerland) (CH)
- Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
- Universität Hamburg (DE)
- Corresponding author
- Hansen, Arne
- ORCID
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-04-27
- Volume
- 158
- Issue
- 1
- Pages
- 164-175
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- PMC
- PMC5837217
- OpenAlex
- W2610084826
- Cited by
- 68
- References
- 59
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 13 · 2023: 8 · 2022: 7 · 2021: 6 · 2020: 13 · 2019: 12 · 2018: 3
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Toxicological Sciences (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- German Centre for Cardiovascular Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- hiPSC-derived cardiomyocytes, engineered heart tissue, lusitropic effect, cardiomyocyte contractility, drug testing, cAMP signaling, beta2-adrenergic agonists, phosphodiesterase III inhibitor, digoxin, tacrolimus, nifedipine, citalopram, lidocaine, formoterol, ryanodine, cardiomyocyte maturation
- MeSH terms
- Calcium, Heart Atria, Humans, Myocardial Infarction, Quality Control, Tissue Engineering, Myocytes, Cardiac, Induced Pluripotent Stem Cells, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.